124 related articles for article (PubMed ID: 38321577)
1. 7-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls.
Evangelatos G; Tentolouris N; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38321577
[TBL] [Abstract][Full Text] [Related]
2. Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3 year prospective study.
Evangelatos G; Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2022 Aug; 61(8):3408-3413. PubMed ID: 34850863
[TBL] [Abstract][Full Text] [Related]
3. Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study.
Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
Semin Arthritis Rheum; 2018 Jun; 47(6):883-889. PubMed ID: 29150207
[TBL] [Abstract][Full Text] [Related]
4. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus.
Papazoglou N; Kravvariti E; Konstantonis G; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2024 Jan; 63(1):50-57. PubMed ID: 37086440
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.
Bolla E; Tentolouris N; Sfikakis PP; Tektonidou MG
Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34921093
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: Association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques.
Bolla E; Tentolouris N; Sfikakis PP; Tektonidou MG
Front Immunol; 2022; 13():1077166. PubMed ID: 36700208
[TBL] [Abstract][Full Text] [Related]
7. Arterial stiffness tested by pulse wave velocity and augmentation index for cardiovascular risk stratification in antiphospholipid syndrome.
Evangelatos G; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2024 Apr; 63(4):1030-1038. PubMed ID: 37294733
[TBL] [Abstract][Full Text] [Related]
8. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study.
Vlachoyiannopoulos PG; Kanellopoulos PG; Ioannidis JP; Tektonidou MG; Mastorakou I; Moutsopoulos HM
Rheumatology (Oxford); 2003 May; 42(5):645-51. PubMed ID: 12709540
[TBL] [Abstract][Full Text] [Related]
9. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.
Jiménez S; García-Criado MA; Tàssies D; Reverter JC; Cervera R; Gilabert MR; Zambón D; Ros E; Bru C; Font J
Rheumatology (Oxford); 2005 Jun; 44(6):756-61. PubMed ID: 15757967
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events.
Frerix M; Stegbauer J; Kreuter A; Weiner SM
Arthritis Res Ther; 2014 Feb; 16(1):R54. PubMed ID: 24548804
[TBL] [Abstract][Full Text] [Related]
11. [Risk factors of thickened intima-media and atherosclerotic plaque development in carotid arteries in patients with systemic lupus erythematosus].
Fischer K
Ann Acad Med Stetin; 2008; 54(2):22-32. PubMed ID: 19374227
[TBL] [Abstract][Full Text] [Related]
12. Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity.
Kravvariti E; Konstantonis G; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2018 Dec; 57(12):2158-2166. PubMed ID: 30102390
[TBL] [Abstract][Full Text] [Related]
13. Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis.
Tektonidou MG; Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Protogerou A
Autoimmun Rev; 2017 Mar; 16(3):308-312. PubMed ID: 28147263
[TBL] [Abstract][Full Text] [Related]
14. High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus.
Svensson C; Eriksson P; Zachrisson H; Sjöwall C
Front Med (Lausanne); 2020; 7():581336. PubMed ID: 33163501
[No Abstract] [Full Text] [Related]
15. Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE.
Panopoulos S; Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
Lupus Sci Med; 2023 Mar; 10(1):. PubMed ID: 36868585
[TBL] [Abstract][Full Text] [Related]
16. Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years.
Ajeganova S; Hafström I; Frostegård J
Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33547230
[TBL] [Abstract][Full Text] [Related]
17. Subclinical Atherosclerosis Burden by 3D Ultrasound in Mid-Life: The PESA Study.
López-Melgar B; Fernández-Friera L; Oliva B; García-Ruiz JM; Peñalvo JL; Gómez-Talavera S; Sánchez-González J; Mendiguren JM; Ibáñez B; Fernández-Ortiz A; Sanz J; Fuster V
J Am Coll Cardiol; 2017 Jul; 70(3):301-313. PubMed ID: 28705310
[TBL] [Abstract][Full Text] [Related]
18. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.
Perez-Sanchez C; Barbarroja N; Messineo S; Ruiz-Limon P; Rodriguez-Ariza A; Jimenez-Gomez Y; Khamashta MA; Collantes-Estevez E; Cuadrado MJ; Aguirre MA; Lopez-Pedrera C
Ann Rheum Dis; 2015 Jul; 74(7):1441-9. PubMed ID: 24618261
[TBL] [Abstract][Full Text] [Related]
19. Disease trends over time and CD4
Baragetti A; Ramirez GA; Magnoni M; Garlaschelli K; Grigore L; Berteotti M; Scotti I; Bozzolo E; Berti A; Camici PG; Catapano AL; Manfredi AA; Ammirati E; Norata GD
Nutr Metab Cardiovasc Dis; 2018 Jan; 28(1):53-63. PubMed ID: 29150407
[TBL] [Abstract][Full Text] [Related]
20. [Significance of antiphospholipid syndrome and antiphospholipid antibodies in patients with systemic lupus erythematosus in estimation of risk of subclinical atherosclerosis development].
Fischer K; Brzosko M; Walecka A; Ostanek L; Sawicki M
Pol Arch Med Wewn; 2007; 117 Suppl():13-7. PubMed ID: 18778013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
